HIV treatment as prevention among injection drug users

Current Opinion in HIV and AIDS

Volumn 7, Issue 2, 2012, Pages 151-156

  Wood, Evan ^a,b   Milloy, Michael John ^a   Montaner, Julio S G ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

AIDS; antiretroviral therapy; HIV; injection drug use; prevention

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; MULTICENTER STUDY; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYRINGE; UNSAFE SEX; VIRUS TRANSMISSION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BALTIMORE; CANADA; DISEASE TRANSMISSION, INFECTIOUS; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL LOAD;

EID: 84857368463     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32834f9927     Document Type: Review

References (55)

1. Leone S, Gregis G, Quinzan G, et al. Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort. Infection 2011; 39:13-20.
2. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41:194-200.
3. Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA 2009; 301:2380-2382.
4. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
5. Montaner JSG. Treatment as prevention: a double hat-trick. Lancet 2011; 378:208-209. This article summarizes the evidence supporting the immediate optimization and implementation of treatment as prevention of HIV infection.
6. Montaner J. IAS 2011 a Critical Turning Point for Treatment as Prevention. In: Proceedings of the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 71-20 July 2011; Rome, Italy. A call to action for the global AIDS community to join together to call for universal endorsement and funding for treatment as prevention by the Past-President of the International AIDS Society.
7. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505. This study (known as HPTN 052) is the first randomized clinical trial to definitively show that early use of antiretroviral therapy by an infected individual reduces the risk of sexual transmission of HIV to an uninfected partner. Reported demographic observations and outcomes data should inform future test and treat strategies.
8. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372:1733-1745.
9. Grigoryan A, Shouse RL, Durant T, et al. HIV infection among injection-drug users: 34 states, 2004-2007. JAMA 2010; 303:126-128.
10. Europe World Health Organization. Regional Office for Europe. European Action Plan for HIV/AIDS 2012-2015: injecting drug users (IDU). http:// www.euro.who.int/en/what-we-do/health-topics/communicable-diseases/hivaids/ policy/injecting-drug-users-idu
11. Mehta SH, Kirk GD, Astemborski J, et al. Temporal trends in highly active antiretroviral therapy initiation among injection drug users in Baltimore, Maryland, 1996-2008. Clin Infect Dis 2010; 50:1664-1671. This study indicates there has been little improvement in HAART initiation among IDUs in Baltimore over a 12-year period highlighting the disparities that exist in access to antiretroviral therapy and HIV care for infected IDUs despite the advent of simplified regimens.
12. Jaimie P. HIV treatment in the criminal justice system: critical knowledge and intervention gaps. AIDS Res Treat 2011; 2011:680617.
13. Hidalgo J, Coombs E, Cobbs WO, et al. Roles and challenges of outreach workers in HIV clinical and support programs serving young racial/ethnic minority men who have sex with men. AIDS Patient Care STDS 2011; 25 (Suppl 1):S15-S22.
14. Wohl AR, Carlos JA, Tejero J, et al. Barriers and unmet need for supportive services for HIV patients in care in Los Angeles County, California. AIDS Patient Care STDS 2011; 25:525-532.
15. Lima VD, Harrigan R, Murray M, et al. Differential impact of adherence on longterm treatment response among naive HIV-infected individuals. AIDS 2008; 22:2371-2380.
16. Nachega B, Marconi C, van Zyl U, et al. HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect Disord Drug Targets 2011; 11:167-174. A review of the role of adherence in the control of HIV disease discussing the potential for flexibility of regimens in this regard and the need for a real-time antiviral therapy adherence monitoring tool to enhance adherence.
17. Wood E, Hogg RS, Lima VD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA 2008; 300:550-554.
18. Larsen MV, Omland LH, Gerstoft J, et al. Impact of injecting drug use on mortality in Danish HIV infected patients: a nation wide population based cohort study. Addiction 2010; 105:529-535. This population-based, prospective cohort study shows that within an environment wherein healthcare is tax paid and antiretroviral therapy is provided free of charge, IDUs are at significantly increased risk of mortality but this is not due to HIV-related causes.
19. Murray M, Hogg RS, Lima VD, et al. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Med 2011 Aug 7. doi: 10.1111/j.1468-1293.2011.00940.x. [Epub ahead of print].
20. Montaner JSG, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376:532-539. We have shown a strong population-level association between increasing HAART coverage, decreased viral load, and decreased number of new HIV diagnoses per year. Reductions in plasma viral load that were documented during HAART expansion provide a plausible mechanistic pathway to account for the observed association The results provide a strong rationale for reexamination of the seek, test and treat approach that has been strongly advocated by theUNJoint Programmeon HIV/AIDS as part of a comprehensive combination prevention strategy.
21. Montaner JSG, Wood E, Kerr T, et al. Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes. J Acquir Immune Defic Syndr 2010; 55:S5-S9. This article reviews the evidence supporting the expansion of provision of HAART to those in medical need, including drug users, as a public health imperative.
22. Johnston KM, Levy AR, Lima VD, et al. Expanding access to HAART: a costeffective approach for treating and preventing HIV. AIDS2010;24:1929-1935. This economic evaluation demonstrates how expanding HAART access is a costeffective measure over the long-term assuming a public health standpoint that all individuals who are eligible for life-saving treatment should receive it.
23. Wood E, Kerr T, Marshall BDL, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 2009; 338:b1649.
24. Kirk G, Galai N, Astemborski J, et al. Decline in community viral load strongly associated with declining HIV incidence among IDU. In: Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections; 27 February to 2 March 2011; Boston, MA, USA; 2011. This study convincingly demonstrates the impact of reducing community virus load on HIV incidence among IDUs and quantifies the relationship between HAART use and HIV incidence risk. These data further support the use of seek, treat and retain strategies to prevent HIV infection among IDUs.
25. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010; 5:e11068. This study identified that reductions in community viral load are associated with reductions in HIV infection, highlighting the potential for wide-scale antiretroviral therapy to reduce HIV transmission at the population level.
26. Fang CT, Hsu HM, Twu SJ, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 2004; 190:879-885.
27. Bezemer D, de Wolf F, Boerlijst MC, et al. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. AIDS 2008; 22:1071-1077. (Pubitemid 351769746)
28. van der Snoek EM, de Wit JBF, Mulder PGH, et al. Incidence of sexually transmitted diseases and HIV infection related to perceived HIV/AIDS threat since highly active antiretroviral therapy availability in men who have sex with men. Sex Transm Dis 2005; 32:170-175. (Pubitemid 40271269)
29. Stolte IG, Dukers NHTM, Geskus RB, et al. Homosexual men change to risky sex when perceiving less threat of HIV/AIDS since availability of highly active antiretroviral therapy: a longitudinal study. AIDS 2004; 18:303-309. (Pubitemid 38253454)
30. Elford J, Bolding G, Sherr L. High-risk sexual behaviour increases among London gay men between 1998 and 2001: what is the role of HIV optimism? AIDS 2002; 16:1537-1544. (Pubitemid 34804219)
31. Williamson LM, Hart GJ. HIV optimism does not explain increases in highrisk sexual behaviour among gay men in Scotland. AIDS 2004; 18:834-835. (Pubitemid 38535022)
32. MacKellar DA, Hou SI, Whalen CC, et al. HIV/AIDS complacency and HIV infection among young men who have sex with men, and the race-specific influence of underlying HAART beliefs. Sex Transm Dis 2011; 38:755-763. Cross-sectional study emphasizing the need for consideration of ethnic differences in order to maximize the effects of HIV prevention intervention programmes.
33. Tun W, Gange SJ, Vlahov D, et al. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIVinfected injection drug users. Clin Infect Dis 2004; 38:1167-1174. (Pubitemid 38951266)
34. Vlahov D, Safaien M, Lai S, et al. Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users. AIDS 2001; 15:2311-2316. (Pubitemid 34059839)
35. Kuyper L, Milloy MJ, Marshall BDL, et al. Does initiation of HIV antiretroviral therapy influence patterns of syringe lending among injection drug users? Addict Behav 2011; 36:560-563. A study of 260 IDUs initiating antiretroviral therapy in Vancouver, British Columbia, demonstrating that concerns regarding increased injection risk behaviours following the initiation of ART were not observed in this setting.
36. Marshall BDL, Milloy MJ, Kerr T, et al. No evidence of increased sexual risk behaviour after initiating antiretroviral therapy among people who inject drugs. AIDS 2010; 24:2271-2278. A study of over 450 HIV-positive IDU showing no increase in risk behaviour after HAART initiation that informs the discussion of provider concerns regarding the potential for increased HIV-related risk behaviour following the initiation of HIV treatment.
37. Smit C, Lindenburg K, Geskus RB, et al. Highly active antiretroviral therapy (HAART) among HIV infected drug users: a prospective cohort study of sexual risk and injecting behaviour. Addiction 2006; 101:433-440. (Pubitemid 43344826)
38. Milloy MJ, Wood E. Transmitted antiretroviral-resistant HIV: a coming anarchy? Lancet Infect Dis 2011; 11:336-337.
39. Wood E, Hogg RS, Yip B, et al. Rates of antiretroviral resistance among HIVinfected patients with and without a history of injection drug use. AIDS 2005; 19:1189-1195. (Pubitemid 41059260)
40. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18:1393-1401. (Pubitemid 38925131)
41. Moore RD, Keruly JC, Chaisson RE. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr 2004; 35:46-51. (Pubitemid 38044781)
42. Werb D, Mills EJ, Montaner JSG, et al. Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users: a meta-analysis. Lancet Infect Dis 2010; 10:464-469.
43. Malta M, Magnanini MMF, Strathdee SA, et al. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav 2010; 14:731-747. Meta-analysis indicating rates of adherence to antiretroviral therapy are similar for IDUs and non-IDUs. This study builds on the accumulating evidence that similar HAART-related health benefits are achievable for HIV-infected IDUs as for non- IDUs.
44. Waldrop-Valverde D, Valverde E. Homelessness and psychological distress as contributors to antiretroviral nonadherence in HIV-positive injecting drug users. AIDS Patient Care STDS 2005; 19:326-334. (Pubitemid 40770656)
45. Carrieri MP, Chesney MA, Spire B, et al. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. Int J Behav Med 2003; 10:1-14. (Pubitemid 36378135)
46. Tucker JS, Burnam MA, Sherbourne CD, et al. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med 2003; 114:573-580. (Pubitemid 36577260)
47. Harrigan PR, Hogg RS, Dong WWY, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191:339-347. (Pubitemid 40139758)
48. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 2004; 53:696-699. (Pubitemid 38660267)
49. Beyrer C, Malinowska-Sempruch K, Kamarulzaman A, et al. Time to act: a call for comprehensive responses to HIV in people who use drugs. Lancet 2010; 376:551-563.
50. Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 2010; 376:355-366.
51. Mimiaga MJ, Safren SA, Dvoryak S, et al. We fear the police, and the police fear us': structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev, Ukraine. AIDS Care 2010; 22:1305-1313.
52. Krusi A, Wood E, Montaner J, et al. Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy 2010; 21:4-9. This article reviews existing literature describing the social and structural determinants of access and adherence to HAART among IDUs, and proposes a conceptual shift towards context-specific interventions is necessary if IDUs are to achieve the full benefits of HAART.
53. Baillargeon J, Giordano TP, Rich JD, et al. Accessing antiretroviral therapy following release from prison. JAMA 2009; 301:848-857.
54. Milloy MJ, Kerr T, Buxton J, et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis 2011; 203:1215-1221. This study shows that, among HIV-seropositive IDUs receiving ART, an increasing burden of incarceration was associated with poorer adherence in a dose-dependent fashion.
55. Westergaard RP, Kirk GD, Richesson DR, et al. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis 2011; 53:725-731. This study highlights the need for continuity of care both during and after incarceration to improve treatment outcomes and prevent the development of viral resistance.